Gain Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Gain Therapeutics R&D Spending Growth & History (GANX)
Gain Therapeutics's r&d spending was $10.2M for fiscal 2025.
View full Gain Therapeutics company overviewGain Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.2M | −$578,276 | −5.36% |
| 2024 | 2024-12-31 | $10.8M | −$729,555 | −6.33% |
| 2023 | 2023-12-31 | $11.5M | $3.1M | +37.52% |
| 2022 | 2022-12-31 | $8.4M | $1.2M | +16.93% |
| 2021 | 2021-12-31 | $7.2M | $4.9M | +217.11% |
| 2020 | 2020-12-31 | $2.3M | — | — |
Gain Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.1M | −$620,769 | −22.50% |
| Q1 2026 | 2026-03-31 | $2.8M | $506,330 | +22.43% |
| Q4 2025 | 2025-12-31 | $2.3M | $1.1M | +91.65% |
| Q3 2025 | 2025-09-30 | $2.8M | $227,788 | +8.69% |
| Q2 2025 | 2025-06-30 | $2.8M | −$1.7M | −37.83% |
| Q1 2025 | 2025-03-31 | $2.3M | −$249,896 | −9.97% |
| Q4 2024 | 2024-12-31 | $1.2M | −$1.1M | −48.41% |
| Q3 2024 | 2024-09-30 | $2.6M | $254,240 | +10.74% |
| Q2 2024 | 2024-06-30 | $4.4M | $449,688 | +11.28% |
| Q1 2024 | 2024-03-31 | $2.5M | −$284,299 | −10.19% |
| Q4 2023 | 2023-12-31 | $2.4M | $100,141 | +4.40% |
| Q3 2023 | 2023-09-30 | $2.4M | $402,698 | +20.50% |
| Q2 2023 | 2023-06-30 | $4.0M | $1.4M | +54.44% |
| Q1 2023 | 2023-03-31 | $2.8M | $1.2M | +79.33% |
| Q4 2022 | 2022-12-31 | $2.3M | $801,369 | +54.42% |
| Q3 2022 | 2022-09-30 | $2.0M | −$511,955 | −20.67% |
| Q2 2022 | 2022-06-30 | $2.6M | $788,716 | +43.98% |
| Q1 2022 | 2022-03-31 | $1.6M | $134,931 | +9.49% |
| Q4 2021 | 2021-12-31 | $1.5M | $496,861 | +50.93% |
| Q3 2021 | 2021-09-30 | $2.5M | $2.0M | +479.40% |
| Q2 2021 | 2021-06-30 | $1.8M | $1.4M | +308.67% |
| Q1 2021 | 2021-03-31 | $1.4M | $1.0M | +240.68% |
| Q4 2020 | 2020-12-31 | $975,612 | — | — |
| Q3 2020 | 2020-09-30 | $427,465 | — | — |
| Q2 2020 | 2020-06-30 | $438,868 | — | — |
| Q1 2020 | 2020-03-31 | $417,259 | — | — |
Gain Therapeutics r&d spending trends
Over the last five fiscal years, Gain Therapeutics's r&d spending increased from $2.3M to $10.2M, a change of $8.0M. The latest reported quarter, Q2 2026, shows $2.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gain Therapeutics source filings ↗